SIP
CRL icon

Stoneridge Investment Partners’s Charles River Laboratories CRL Stock Holding History

Stoneridge Investment Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-19,634
Closed -$1.5M – 316
2016
Q4 		$1.5M Buy
+19,634
New +$1.49M 0.2% 138

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Stoneridge Investment Partners's CRL Position: Q1 2017 in Review

Stoneridge Investment Partners sold out of Charles River Laboratories (CRL) in Q1 2017, closing a stake of 19,634 shares — an estimated $1.5M sold.

Stoneridge Investment Partners first reported a position in CRL in Q4 2016 and held it in 1 quarter. The position peaked at $1.5M in Q4 2016. 300 funds tracked by Wall St. Rank hold CRL as of Q1 2017.

  • Stoneridge Investment Partners reported no remaining Charles River Laboratories position as of Q1 2017 after selling out during the quarter.
  • Stoneridge Investment Partners sold 19,634 Charles River Laboratories shares in Q1 2017, an estimated $1.5M.
  • Stoneridge Investment Partners first reported a position in Charles River Laboratories in Q4 2016 and held it in 1 quarter.
  • Stoneridge Investment Partners's Charles River Laboratories position peaked at $1.5M in Q4 2016.
  • 300 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2017.

Based on Stoneridge Investment Partners's 13F filing for Q1 2017, filed 1 May 2017.